Cui Xueping, Wu Chunmei, Xu Yusheng, Zou Chunchu, Jiang Xiayun
Department of Pharmacy, Lishui People's Hospital, Lishui, 323000, China.
Department of Pharmacy, Lishui Second People's Hospital, Lishui, 323000, China.
Heliyon. 2024 Jul 14;10(14):e34539. doi: 10.1016/j.heliyon.2024.e34539. eCollection 2024 Jul 30.
The traditional Chinese medicine (TCM) formula Ento-PB containing (Linnaeus) (Blattidae) and Hand.-Mazz. (Compositae) has great potential for treating inflammation. Thus, this study aimed to explore the pharmacodynamic effect of Ento-PB on DSS-induced ulcerative colitis in BALB/c mice, and its effects on immune function, JAK2/STAT3-related signaling pathways and intestinal flora in UC mice. It was identified that the extract Ento-PB mainly contained 20 compounds, accounting for 78.50 % of the total peak area. Compared with the model group, each dose group of Ento-PB could reduce the DAI score, colon index, CMDI score and colon HS score of mice to varying degrees ( < 0.05 or < 0.01). Ento-PB can reduce the content of IL-1β, TNF-α, IFN-γ in serum and IL-7 and IL-17 in colonic tissue, and increase IL-2, IL-10 in serum and EGF in colonic mucosa, TGF-β1 expression level ( < 0.05 or < 0.01). In conclusion, Ento-PB has a good therapeutic effect on DSS-induced UC mice. Its mechanism of action may be to up-regulate the levels of IL-2, IL-10, EGF, IL-22 and TGF-β1, and down-regulate the levels of TNF-α,IFN-γ, IL-7 and IL-17 in UC mice. This provides sufficient experimental basis for the clinical treatment of UC with Ento-PB.
含有蜚蠊（蜚蠊科）和翼茎风毛菊（菊科）的中药方剂Ento - PB在治疗炎症方面具有巨大潜力。因此，本研究旨在探讨Ento - PB对葡聚糖硫酸钠（DSS）诱导的BALB/c小鼠溃疡性结肠炎的药效学作用，及其对UC小鼠免疫功能、JAK2/STAT3相关信号通路和肠道菌群的影响。经鉴定，Ento - PB提取物主要含有20种化合物，占总峰面积的78.50%。与模型组相比，Ento - PB各剂量组均可不同程度降低小鼠的疾病活动指数（DAI）评分、结肠指数、结肠黏膜损伤指数（CMDI）评分和结肠组织苏木精-伊红（HS）评分（P<0.05或P<0.01）。Ento - PB可降低血清中白细胞介素-1β（IL - 1β）、肿瘤坏死因子-α（TNF - α）、干扰素-γ（IFN - γ）以及结肠组织中IL - 7和IL - 17的含量，并增加血清中IL - 2、IL - 10以及结肠黏膜中表皮生长因子（EGF）、转化生长因子-β1（TGF - β1）的表达水平（P<0.05或P<0.01）。综上所述，Ento - PB对DSS诱导的UC小鼠具有良好的治疗作用。其作用机制可能是上调UC小鼠中IL - 2、IL - 10、EGF、IL - 22和TGF - β1的水平，下调TNF - α、IFN - γ、IL - 7和IL - 17的水平。这为Ento - PB临床治疗UC提供了充分的实验依据。
